Literature DB >> 19176868

Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis.

Andrea M Stringer1, Rachel J Gibson, Richard M Logan, Joanne M Bowen, Ann S J Yeoh, Juliette Hamilton, Dorothy M K Keefe.   

Abstract

5-Fluorouracil (5-FU) is a commonly used chemotherapy agent in clinical oncology practice. Two of its major side effects are mucositis and diarrhoea. The structure of mucins offers mucosal protection, and allows maintenance of intestinal flora by providing attachment sites and preventing bacterial overgrowth and/or penetration. The aim of this study was to investigate changes in mucin secretion and microflora following treatment with 5-FU. Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. Rats were killed at various time points after treatment. Control rats received no treatment. Jejunum, colon and faecal samples were collected. Standard microbiological culture techniques were used to identify bacteria, and real-time PCR was used to quantify bacteria in faecal samples. Goblet cells and cavitated goblet cells (having undergone mucus exocytosis) were also counted. Statistical analysis was carried out using Kruskal-Wallis test, a non-parametric method of testing equality of group medians. Following treatment with 5-FU, we showed decreases in Clostridium spp., Lactobacillus spp. and Streptococcus spp., and an increase in Escherichia spp. in the jejunum. In the colon, 5-FU caused decreases in Enterococcus spp., Lactobacillus spp. and Streptococcus spp. Real-time PCR of faecal samples showed decreasing trends in Lactobacillus spp. and Bacteroides spp., and an increasing trend in E. coli. Significant increases (P < 0.05) were seen in Clostridium spp. and Staphylococcus spp. at 24 h. Goblet cell numbers decreased significantly in the jejunum from 24-72 h, with a significant increase in the percentage of cavitated goblet cells. In conclusion, 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes could result in systemic effects and, in particular, may contribute to the development of chemotherapy-induced mucositis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176868     DOI: 10.3181/0810-RM-301

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  54 in total

1.  Mixed effects of caffeic acid phenethyl ester (CAPE) on joint inflammation, bone loss and gastrointestinal inflammation in a murine model of collagen antibody-induced arthritis.

Authors:  Bonnie Williams; Eleni Tsangari; Romany Stansborough; Victor Marino; Melissa Cantley; Anak Dharmapatni; Rachel Gibson; Egon Perilli; Tania Crotti
Journal:  Inflammopharmacology       Date:  2017-01-03       Impact factor: 4.473

Review 2.  Tachykinin peptide, substance P, and its receptor NK-1R play an important role in alimentary tract mucosal inflammation during cytotoxic therapy.

Authors:  P S Satheeshkumar; Minu P Mohan
Journal:  Dig Dis Sci       Date:  2014-07-01       Impact factor: 3.199

Review 3.  Current evidence for vitamin D in intestinal function and disease.

Authors:  Mohammadhossein Hassanshahi; Paul H Anderson; Cyan L Sylvester; Andrea M Stringer
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-31

4.  The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota-Mediated Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Tingting Wang; Chaogang Fan; Anran Yao; Xingwei Xu; Guoxing Zheng; Yun You; Changying Jiang; Xueqiang Zhao; Yayi Hou; Mien-Chie Hung; Xin Lin
Journal:  Immunity       Date:  2018-09-18       Impact factor: 31.745

5.  Gut mycobiota and adenomas.

Authors:  Chunguang Luan; Huifang Miao; Baoli Zhu
Journal:  Gut Microbes       Date:  2015

Review 6.  Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.

Authors:  Barbara Vanhoecke; Emma Bateman; Bronwen Mayo; Eline Vanlancker; Andrea Stringer; Daniel Thorpe; Dorothy Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

Review 7.  Mycobiota in gastrointestinal diseases.

Authors:  Pranab K Mukherjee; Boualem Sendid; Gautier Hoarau; Jean-Frédéric Colombel; Daniel Poulain; Mahmoud A Ghannoum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-11       Impact factor: 46.802

Review 8.  The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis.

Authors:  Michel J van Vliet; Hermie J M Harmsen; Eveline S J M de Bont; Wim J E Tissing
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

9.  Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.

Authors:  Noor Al-Dasooqi; Joanne Bowen; Colin Bennett; John Finnie; Dorothy Keefe; Rachel Gibson
Journal:  Support Care Cancer       Date:  2016-09-20       Impact factor: 3.603

Review 10.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.